Apixaban versus Warfarin in Patients with Atrial Fibrillation
2011 · New England Journal of Medicine · 8,769 citations
https://doi.org/10.1056/nejmoa1107039
R
Rafael Díaz
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
39
Papers
12.2K
Citations
16
h-index
18
i10-index
Rafael Díaz is an academic researcher from Instituto Cardiovascular de Rosario. The author has contributed to research in topics: Cardiovascular Function and Risk Factors & Cardiac pacing and defibrillation studies & Heart Failure Treatment and Management. The author has an h-index of 16, co-authored 34 publications.
Papers by this author
worksThrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
2011 · New England Journal of Medicine · 751 citations
https://doi.org/10.1056/nejmoa1109719
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
2023 · Journal of Cardiac Failure · 7 citations
https://doi.org/10.1016/j.cardfail.2023.08.020
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
2026 · European Journal of Heart Failure · 0 citations
https://doi.org/10.1093/ejhf/xuag023
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat